Skip to main content
. Author manuscript; available in PMC: 2006 Sep 8.
Published in final edited form as: J Clin Endocrinol Metab. 2006 Apr 11;91(9):3349–3354. doi: 10.1210/jc.2005-2226

Table 2.

TZD use in the Health ABC cohort over four years

BL-Year 4 (4 yrs) BL-Yr 2 (1st 2 yrs) Yr 2-Yr 4 (2nd 2 yrs)
Number reporting useb
Any TZD 69 32 64
Troglitazone 22 22 13
Pioglitazone 30 5 30
Rosiglitazone 31 7 31
Mean use a (yrs)
Any TZD 1.67±1.03 1.09±0.60 1.25±0.44
a

Mean ± standard

b

Numbers reporting use of the three specific TZDs do not total to those using “any TZD” since a participant may have used more than one type of TZD during the follow-up period.